LEXX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (21 May 2024 @ 04:00):

Stats
今日成交量	343 955
平均成交量	478 383
市值	37.63M
EPS	$0 ( 2024-04-12 )
下一个收益日期	( $-0.130 ) 2024-07-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.36
ATR14	$0.0280 (0.96%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-14	Carle Vanessa	Sell	2 500	Stock Options
2024-05-14	Carle Vanessa	Buy	2 500	common shares
2024-04-26	Carle Vanessa	Buy	10 000	Stock Options
2024-04-26	Turkel Catherine C.	Buy	5 000	Stock Options
2024-04-26	Baxter Nicholas W	Buy	5 000	Stock Options

INSIDER POWER
10.87
Last 99 transactions
Buy: 3 496 310 \| Sell: 1 994 235

音量相关性

長: -0.01 (neutral)

短: 0.27 (neutral)

Signal:(48.242) Neutral

Lexaria Bioscience Corp. 相关性

10 最正相关
AIHS	0.867
PASG	0.86
POWL	0.856
SLN	0.856
VTYX	0.856
CLBT	0.851
MRUS	0.85
KYMR	0.85
PEPG	0.847
QRTEP	0.845

10 最负相关
MDRX	-0.823
DPRO	-0.816

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Lexaria Bioscience Corp. 相关性 - 货币/商品

-0.15
( neutral )

0.28
( neutral )

0.00
( neutral )

0.19
( neutral )

0.69
( moderate )

-0.38
( neutral )

Lexaria Bioscience Corp. 财务报表

Annual	2023
营收:	$226 208
毛利润:	$194 708 (86.07 %)
EPS:	$-1.010

FY	2023
营收:	$226 208
毛利润:	$194 708 (86.07 %)
EPS:	$-1.010

FY	2022
营收:	$255 397
毛利润:	$183 556 (71.87 %)
EPS:	$-1.240

FY	2021
营收:	$722 738
毛利润:	$547 392 (75.74 %)
EPS:	$-0.950

Financial Reports:

No articles found.

Lexaria Bioscience Corp. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Lexaria Bioscience Corp.

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.